
- The Center Core
- Substance Abuse Treatment Pathways for Employee Groups
- Profiling and Incentives in Behavioral Health Care
- Substance Abuse Treatment and Work Programs
- CSAT Supplement to NIDA Center - Washington Circle (WC) Substance Abuse Performance Measures
- Research Supplement to Promote Diversity in Health-Related Research
- Clinician Characteristics and Substance Abuse Performance Measures
- Problem Prescribing among Nursing Home Residents
- Cost-Effectiveness, Cost-Benefit, and Cost Utility of Enhanced Medical Management in the Prescription Opioid Addiction Treatment Study (POATS; CTN-0030): Data Collection Supplement
- Effect of Parity Legislation on Substance Abuse Treatment
- Substance Abuse Performance Measures & Narcotics Anonymous Group Participation
Brandeis/Harvard Center on Managed Care and Drug Abuse Treatment
Research Projects
The Center Core provides the organizational and administrative structure and support functions conducive to enhancing synergy among the components, fostering innovation, and promoting productive interaction among Center staff and students, under joint leadership from Brandeis and Harvard. Each organization provides a unique set of substantive skills that strengthen the collective expertise offered by the Center, which overlap in some cases and are complementary in others. Considered together, they constitute the structural foundation necessary to tackle the sophisticated issues and to conduct coordinated, comprehensive research on managed care and substance abuse treatment.
Under the direction of the co-Directors and Deputy Directors, the Internal Advisory Board (IAB) provides the main focus of coordination within the Center. Complementing the function of the IAB, an External Advisory Board (EAB), composed of distinguished experts in a range of fields, provides input to the Center and assists in the dissemination of the Center's findings.
In addition to activities internal to the NIDA Center, activities supported by the Core have included:
Seminars:
- The next stage of the health quality movement (Margaret O'Kane)
- What do spacecraft communications, wine making and health outcomes have in common (ProVentive, Inc.)
- Repositioning EAPs for the new millenium (Dale Masi)
- Reconsidering addiction treatment: a business perspective (A. Thomas McLellan)
- Delaware's pay-for-performance initiative in the public sector (Jack Kemp)
- Using systems to improve substance abuse treatment (NIATx) (Dave Gustafson)
- Organizational theory as a platform for substance abuse services research (Paul Roman)
Statistical Workshops:
- Statistical analyses in the context of small sample size
- Propensity scores
- Hierarchical linear modeling
- Survival analysis techniques
Other Collaborations:
- Washington Circle – new performance measures development


Substance Abuse Treatment Pathways for Employee Groups
Facilitating substance abuse treatment access and engagement is critical because drug and alcohol disorders are frequently not addressed despite availability of effective treatment. In the private sector, there are several potential pathways into specialty treatment, including managed behavioral health carve-out plans and employee assistance programs (EAPs) that can be provided by different organizations or by the same managed behavioral health care organization. The study is investigating the roles and interrelationship between these employer-sponsored programs as well as other resources for substance abuse problems regarding treatment access and engagement.
In this collaborative project with MHN, a national managed behavioral health care organization with enrollment of about 10 million members, the Brandeis/Harvard research team is making use of diverse and complementary data sources to span 1999-2008, including administrative data and an enrollee survey, to address the following research goals:
- Describe substance abuse access, utilization, costs, and performance indicators in EAP and managed behavioral health products
- Compare findings for integrated (EAP/managed behavioral health) versus stand-alone component products
- Investigate other influences on utilization from employer, plan, provider and individual domains (e.g. workplace policies, state parity laws, utilization management procedures, client experience of care, employee beliefs about confidentiality, pressure to enter treatment)
This study will enable the development of a multifaceted model of substance abuse treatment access and engagement that includes behavioral health product type/structure as well as factors from other key domains. The results will be of interest to employers, insurers, policymakers and others concerned with improving access to substance abuse treatment in privately insured populations.


Profiling and Incentives in Behavioral Health Care
Although managed behavioral health care has achieved impressive cost reductions in the public sector, its relationship to quality has been a continuing concern, particularly when disadvantaged groups are affected. This research explores innovative ways to improve the quality of care for low-income general assistance clients who receive substance abuse treatment under the state of Connecticut’s managed behavioral health care system.
Using a design that randomizes treatment agencies to conditions, this study is comparing three approaches to improving the quality of substance abuse treatment among publicly-funded treatment for substance abuse in the state of Connecticut. So far, 54 treatment facilities providing detox or residential treatment have been randomized to one of two conditions: (1) basic profiling, or (2) basic plus enhanced profiling. Collectively, these agencies serve approximately 25,000 Connecticut state-administered general assistance (SAGA) clients who are covered annually under Connecticut's general assistance behavioral health care program (GAPBH).
Basic profiling consists of the state’s Department of Mental Health and Addiction Services (DMHAS) mailing a one-page basic profile to the chief executive of each treatment agency, for each level of care it provides. The basic profile, which covers treatment exits (discharges) from treatment in the last 3 or 6 months, shows the number of exits during the recall period and the percentage of these clients who connected to care at a lower level of intensity (a favorable outcome) or were readmitted to a higher level of care (an unfavorable outcome). Basic profiles had been distributed from October 2001 through April 2004, and, after a hiatus, were resumed in October 2005.
Agencies randomized to the enhanced group receive coaching from a team of DMHAS regional managers and their staff consisting of additional information and tools, and encouragement and training in quality improvement techniques and best practices. This coaching is focused on key profile measures and generally being provided through in-person meetings twice per year.
In 2007, the project plans to randomize half of the agencies in the enhanced profiling group into an incentives group that will receive a package of financial and non-financial incentives if they perform in the top quartile of their level of care. These agencies will be rewarded with administrative, referral, recognition, and financial incentives during year two and year three. Whether or not these agencies are randomized into the incentives group, these agencies will continue to receive advanced profiling.
Site visits and provider surveys will be used to obtain qualitative information about the awareness of the treatment arms. Next, we will evaluate the impact of profiling through administrative data to see whether there are changes in client transitions and costs of subsequent care. We have been advising DMHAS regarding the development of a case mix index to adjust for differences in the patient population of different agencies. The project will also conduct developmental work evaluating performance in agencies with few discharges during the reference period. In this case, information from the agencies’ past performance, characteristics of the agency, and performance of similar agencies may be incorporated into the analysis.


Substance Abuse Treatment and Work Programs
The interrelations among substance abuse, treatment and work are complex and have increasing policy importance. At the same time, public policy related to substance abuse disorders, their treatment, and income support programs and work is poorly conceived and controversial. For some purposes (public and most private health insurance) substance abuse is regarded as an illness worthy of collective financial support. For other purposes (federal disability programs) substance abuse fails to qualify as a reason for support. Our research explores the design of payment incentives for programs that seek to offer services to support labor market entry for income support program participants with substance abuse disorders. We do so with theoretical and empirical methods, and apply these results in policy simulations.
We intend to develop a novel conceptual framework drawing from the field of health care payment systems, where methodologies for deriving the characteristics of “optimal payment systems” is highly developed. Many analogies can be drawn between health payment systems and payment systems for work-related services that give us a starting point for this research. Using methods from labor economics, we are conducting empirical work to quantify important relationships using several data sets. Our primary interest is in the factors associated with return to successful employment. We are studying the characteristics of beneficiaries, how these relate to return to work, and how this favorable outcome is related to program organization and financing. We will apply the findings from our theoretical and empirical analysis to state and federal policies related to substance abuse and employment.
Our specific aims are as follows:
- To set forth an economic framework that integrates beneficiary incentives and service provider incentives for successful return to work by people suffering from substance abuse disorders.
- To conduct a series of empirical analyses to estimate key parameters to design a payment system to encourage successful return to work by people with substance abuse disorders. In particular we will seek to develop evidence on the use of performance-based evaluations for providers and program design incentives for potential workers with substance abuse disorders.
- To build a policy simulation model capable of being applied to a range of policies that affect the return to work of people with substance abuse disorders that participate in income support programs.


CSAT Supplement to NIDA Center - Washington Circle (WC) Substance Abuse Performance Measures
Funded by the Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), the scope of work includes the Washington Circle (WC) Public Sector Project in which 12 states will adapt the WC substance abuse performance measures, developed for commercial health plans, for use in the public sector.
The WC performance measures that are being adapted for the public sector are identification of substance use disorders, initiation into treatment, and engagement in treatment. The participant states are Arizona, Connecticut, Delaware, Kansas, Massachusetts, Nevada, New York, North Carolina, Oklahoma, Tennessee, Vermont, and Washington.
The main goals of the project are to:
- Explore the data elements currently collected by states for their substance abuse treatment facilities and the structure of their administrative databases.
- Work with states to adapt specifications for the WC performance measures for the public sector.
- Pilot test the WC performance measures by using state administrative data to calculate measures.
- Support states in using performance measures to monitor quality of care.


Research Supplement to Promote Diversity in Health-Related Research
This diversity supplement to the Brandeis/Harvard Center on Managed Care and Substance Abuse Treatment supports Dr. Dunigan’s independent research development in two important ways: 1) It facilitates learning about current developments in the study of race within the context of behavioral health system performance measures and outcomes; and 2) it expands upon current knowledge of statistical methods to better differentiate organizational and personal level influences on substance abuse treatment outcomes. The ultimate aim of this diversity supplement is for Dr. Dunigan to develop independent research studies.
The diversity supplement relies primarily on the research, statistical, mentoring and dissemination support of the Core, and on the data and methods of the Center project “Profiling and Incentives in Behavioral Health Care,” as well as other collaborations developed as part of these activities. Dr. Dunigan is evaluating the contribution of profiling and incentives in improving managed behavioral health care for minority General Assistance clients who receive substance abuse treatment under Connecticut’s managed behavioral health care program. Results from this research can inform the development of a larger, more generalizable study. Understanding the impact of profiling and incentives on providers serving minority clients is vital for understanding the causes and factors associated with disparities in treatment outcomes, and for the development of more effective intervention strategies aimed towards marginalized populations.
This diversity supplement has the following aims:
- Explore whether the proportion of minority clients served by an agency independently affect process outcomes, and examine the interaction effect of minority case mix with the profiling incentives intervention
- Explore whether African-American and Latino males have different process outcomes than each other, white males, and females, controlling for organizational and individual characteristics
- Based on findings from the above aims, develop a theoretical framework and measurement strategy to further analyze the differential outcomes for African-American and Latino males
- Develop a study on treatment access and utilization among African-American adults while incarcerated and during the process of community re-entry, and the impact treatment has on consumer outcomes


Clinician Characteristics and Substance Abuse Performance Measures
To improve quality of treatment, performance measurement is increasingly being used. So far, performance measures for substance abuse services measure the status of individual clients, typically aggregated to the level of health plans or treatment facilities. However, in privately funded treatment, individual office-based clinicians are key providers of care. Little research has examined the relationship between clinician characteristics and aggregate performance for treatment of substance use disorders. In addition, treatment for substance use disorders under private insurance has been under-explored along a number of dimensions, including quality. By focusing on the role of clinician characteristics in performance measures, this study can contribute to the understanding of how to improve the quality of substance abuse treatment.
Therefore, we aim to identify specific clinician characteristics that are associated with better performance, and thus higher quality treatment of substance use disorders, within the context of private health plans. Clinician characteristics, obtained from credentialing data, will center on expertise treating substance use disorders and other professional characteristics. This study will use data from a large managed behavioral health organization and will build upon substance abuse performance measures developed by the Washington Circle and adopted by the National Committee on Quality Assurance, to address the following specific aims
Examine rates and predictors of initiation into substance abuse treatment, by characteristics of treating clinicians.
- Examine rates and predictors of engagement in substance abuse treatment, by characteristics of treating clinicians; and
- Examine rates and predictors of remaining in treatment for at least 90 days, by characteristics of treating clinicians.
A further understanding of this relationship could provide guidance to health plans, purchasers and consumers to better match clinicians and clients with appropriate, quality care for treatment of substance use disorders, to improve the process of care, using commonly available data. Such an enhanced framework can also be used to provide feedback to clinicians, which has been linked to quality improvements. With these performance measures ultimately linked to better outcomes, this analysis is an essential step in the process to improve outcomes.


Problem Prescribing among Nursing Home Residents
Using data from the 2004 National Nursing Home Survey (NNHS), we will assess prescription drug use of nursing home residents nationally and the relationship of prescribing patterns of interest with facility characteristics of interest. We will focus on two drug classes – benzodiazepines and anti-psychotics – that have raised previous concerns about misuse, over-use, and abuse among nursing home residents, especially those individuals with cognitive impairments.
The new Prescribed Medications (PM) module data from the 2004 NNHS provide an important opportunity to advance understanding of prescription drug use among nursing home residents. In creating a linked resident-facility file, we will have the ability to test associations between facility characteristics of interest and prescribing patterns that may be problematic in our two selected drug classes. Our focus on benzodiazepines and anti-psychotic medications will build on a previous literature that identifies prescribing in these classes as problematic. For instance, the HHS Office of the Inspector General recently studied psychotropic drug use in nursing homes because of concerns that have been raised about whether these medications might constitute “chemical restraints”, http://oig.hhs.gov/oei/reports/oei-02-00-00490.pdf). Clinical and policy implications of our findings will be discussed.
The NNHS uses a stratified two-stage probability design collecting detailed, representative facility- and resident-level information from nursing homes and their current residents. The final samples from the 2004 survey consisted of 1,500 facilities and up to 12 current residents from each facility. Our study will merge the PM module of the NNHS with other facility and resident information. The PM module reports information on medication use by individual residents, the clinical rationale for prescribing, and any adverse drug events during the last 30 days. By working with the data through the National Center for Health Statistics, we will merge these individual data with information from the facility file of the NNHS and with information from the On-Line Survey Certification and Reporting (OSCAR) system.


Cost-Effectiveness, Cost-Benefit, and Cost Utility of Enhanced Medical Management in the Prescription Opioid Addiction Treatment Study (POATS; CTN-0030): Data Collection Supplement
This supplement collects data necessary for economic analyses associated with the Prescription Opioid Addiction Treatment Study (POATS) of the Clinical Trials Network (CTN-0030). Since a goal of the POATS study is to seek an effective treatment for patients with chronic pain and non-heroin opioid addiction, a cost-effectiveness analysis specifically focusing on this population is a great addition to the field. This is a particularly important focus with the increasing numbers of individuals who have become dependent upon prescription opioids.
POATS is a multi-center Clinical Trials Network study examining optimal combinations of buprenorphine-naloxone and drug counseling for patients with opioid analgesic dependence. POATS compares two different models of care for this population: office-based opioid treatment by a physician (standard medical management, or SMM) versus a drug abuse treatment program model (enhanced medical management, or EMM). POATS hypothesizes that adding more intensive individual drug counseling to standard medical management will improve treatment outcomes for this population, both in a relatively brief taper treatment and in a longer treatment. However, it is unclear how much benefit will be gained, and at what cost. EMM is clearly a more complex and expensive treatment approach than SMM.
If EMM is found superior to SMM, it will be important to determine the cost of incremental benefits from this model, and for various components of the model, in order to determine whether EMM is a cost-effective mode of treatment. While the current POATS study already collects considerable clinical demographic, social, behavioral and medical data from subjects, additional data are necessary for economic analyses, to determine treatment costs and assign values to outcomes. The supplement will thus collect data to calculate medical costs associated with each type of treatment and to inform additional studies that will conduct economic analyses of the benefits of treatment in this population. Collection of these data will also enable a preliminary cost-effectiveness analysis of SMM versus EMM, with outcomes defined as success or failure in treatment. Further, the economic data collected and analyzed in the proposed research will guide development of larger health services research studies, including but not limited to economic evaluations, particularly cost effectiveness, cost benefit, and cost utility analyses of the POATS study treatments.
For additional information on the POATS study, led by the New England node of the Clinical Trials Network (R. Weiss, P.I., McLean Hospital), visit the following website:


Effect of Parity Legislation on Substance Abuse Treatment
Parity coverage for substance abuse treatment services has been debated recently at both the state and federal levels of government. Traditionally, insurance coverage for treatment of addictive disorders has been strictly limited under private insurance and even many Medicaid programs. Objections to parity of coverage for substance abuse services at the same level as medical services typically focus on the cost of the policy. In January of 2001, the FEBHP implemented parity for both mental health and substance abuse services within a managed care network or for all indemnity benefits. We used a quasi-experimental design where the FEHB experience before and after the parity policy was compared to a matched set of private insurance comparison plans. We used archival health plan enrollment and claims data from 6 plans from the FEHB for the period 1999-2002 (2 years before and 2 years after parity implementation). Using a difference-in-differences approach, we estimated logistic regression models of the probability of SA service use and generalized linear models of SA total spending/SA plan spending conditional on use for the 6 FEHB plans (pulled together as they share the same benefit design and belong to the same organization) and a matched set of non-FEHB comparison plans in the same regions. The specific aims of this study are to examine the impact of parity for substance abuse treatment on the cost of substance abuse care and on indicators of the quality of substance abuse treatment.

Substance Abuse Performance Measures & Narcotics Anonymous Group Participation
Attendance at addiction-related self-help groups (e.g., Alcoholics Anonymous (AA), Narcotics Anonymous (NA)) after substance abuse treatment has been linked to better client outcomes; however, many clients do not participate in self-help groups after their treatment has ended. While some studies have investigated the relationship of sociodemographic and other individual characteristics to self-help group participation, little research has examined treatment-related factors, including whether the quality of care delivered during substance abuse treatment influences subsequent involvement in these groups. This study will begin to address the existing research gap by examining whether during-treatment process measures of quality are related to NA participation after treatment within a national sample of alcohol and drug abusers treated at specialty substance abuse treatment facilities. During-treatment process measures of quality will be based on performance indicators designed or under development by the Washington Circle Group, and will include engagement in treatment, retention in treatment and maintenance of treatment effects. These performance indicators could be used to indicate which clients are likely to attend (or not) self-help groups after discharge. The analysis will provide empirical evidence that may inform policymakers and treatment providers about the potential use of incentives to encourage NA group participation following substance abuse treatment, allowing better use of limited resources and improving the quality of treatment.




